Rezolute Stock

Rezolute EBIT

The EBIT of Rezolute (RZLT) as of Jul 23, 2026 is -79.89 M USD. In the previous year, EBIT was -70.42 M USD — a change of 13.45% (lower).

EBIT

-79.89 MUSD

YoY

13.45%

Last updated:

In 2026, Rezolute's EBIT was -79.89 M USD, a 13.45% increase from the -70.42 M USD EBIT recorded in the previous year.

The Rezolute EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-70.42 base
Jan 1, 2025
-79.89 base
Jan 1, 2026 (e)
-77.40 base
Jan 1, 2027 (e)
-83.83 base
Jan 1, 2028 (e)
-59.06 base
Jan 1, 2029 (e)
15.04 base
Jan 1, 2030 (e)
161.67 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 161.67
2029 est 15.04
2028 est -59.06
2027 est -83.83
2026 est -77.40
2025 -79.89
2024 -70.42
2023 -55.99
2022 -41.84
2021 -22.90
2020 -20.52
2019 -25.90
2018 -26.38
2017 -20.32
2016 -14.95
2015 -10.70
2014 -5.18
2013 -6.11
2012 -0.05
2011 -0.04
2010 -
Access this data via the Eulerpool API

Rezolute Revenue

Rezolute Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
0.00 USD
-70.42 M USD
-68.46 M USD
Jan 1, 2025
0.00 USD
-79.89 M USD
-74.41 M USD
Jan 1, 2026 (e)
0.00 USD
-77.40 M USD
-54.26 M USD
Jan 1, 2027 (e)
18.15 M USD
-83.83 M USD
-52.17 M USD
Jan 1, 2028 (e)
87.40 M USD
-59.06 M USD
-25.58 M USD
Jan 1, 2029 (e)
149.57 M USD
15.04 M USD
-101.94 M USD
Jan 1, 2030 (e)
292.64 M USD
161.67 M USD
94.32 M USD
Jan 1, 2031 (e)
380.50 M USD
0.00 USD
144.71 M USD

Rezolute Margins

Rezolute stock margins

The Rezolute margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rezolute. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rezolute.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-461.89 %
-287.46 %
Jan 1, 2028 (e)
0.00 %
-67.58 %
-29.27 %
Jan 1, 2029 (e)
0.00 %
10.05 %
-68.15 %
Jan 1, 2030 (e)
0.00 %
55.25 %
32.23 %
Jan 1, 2031 (e)
0.00 %
0.00 %
38.03 %

Rezolute Stock analysis

What does Rezolute do? Rezolute Inc. is a bio-pharmaceutical company that was founded in 2010 in California. The company specializes in the research and development of innovative therapies for the treatment of rare metabolic and endocrine diseases. The business model of Rezolute is to develop innovative solutions and treatment approaches for diseases that currently have insufficient treatment options. The company is actively working to expand its product pipeline and explore new treatment methods in order to give hope and prospects for a better quality of life to suffering patients. Rezolute is active in three main areas: diabetes and metabolic diseases, diseases of the endocrine system, and protein-based therapy platforms. Each of these areas is of great importance in combating rare diseases that are often overlooked by the pharmaceutical industry. The diabetes and metabolic diseases category is the core business of Rezolute Inc. The company strives to develop innovative therapies for the treatment of diabetes itself and its comorbidities. This includes diseases of the cardiovascular system and kidney diseases, which are common among diabetes patients. In the category of endocrine diseases, the company is working on the development of targeted therapies for the treatment of diseases such as hypothyroidism (an underactive thyroid) and hypopituitarism (a deficiency of hormones produced by the pituitary gland). These diseases are often overlooked by the pharmaceutical industry as they occur less frequently compared to other diseases. The protein-based therapy platforms are technologically advanced and have the potential to offer new treatment options. Rezolute utilizes its own proprietary technologies for the development of immunoglobulins and drugs that specifically target certain molecules. The company is also researching compounds that can influence the immune system to combat inflammation and autoimmune diseases. Rezolute currently has several therapy options in development. The company is working on RZ358, an oral insulin formulation for the treatment of diabetes; RZ402, a drug for the treatment of pancreatitis (inflammation of the pancreas); and RZ402, a drug for the treatment of pancreatitis (inflammation of the pancreas). The company has also obtained orphan drug status to develop RZ358, its innovative therapy for the treatment of Congenital Hyperinsulinism (CHI), a rare, congenital endocrine disorder. Rezolute has established itself as an important player in the global bio-pharmaceutical market. The company is committed to improving the lives of patients suffering from rare diseases by developing innovative treatment options. With a dedicated team of scientists and researchers, the company strives to push the boundaries of science and develop the next generation of innovative therapies that have the potential to improve the lives of patients. Rezolute is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Rezolute's EBIT

Rezolute's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Rezolute's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Rezolute's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Rezolute’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Rezolute stock

EBIT of Rezolute is -79.89 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Rezolute

All Key Metrics — Rezolute